| Literature DB >> 30872149 |
Ali Alikhan1, Christopher Sayed2, Afsaneh Alavi3, Raed Alhusayen3, Alain Brassard4, Craig Burkhart5, Karen Crowell6, Daniel B Eisen4, Alice B Gottlieb7, Iltefat Hamzavi8, Paul G Hazen9, Tara Jaleel10, Alexa B Kimball11, Joslyn Kirby12, Michelle A Lowes13, Robert Micheletti14, Angela Miller8, Haley B Naik15, Dennis Orgill16, Yves Poulin17.
Abstract
Hidradenitis suppurativa is a severe and debilitating dermatologic disease. Clinical management is challenging and consists of both medical and surgical approaches, which must often be combined for best outcomes. Therapeutic approaches have evolved rapidly in the last decade and include the use of topical therapies, systemic antibiotics, hormonal therapies, and a wide range of immunomodulating medications. An evidence-based guideline is presented to support health care practitioners as they select optimal medical management strategies and is reviewed in this second part of the management guidelines. A therapeutic algorithm informed by the evidence available at the time of the review is provided.Entities:
Keywords: Nd:YAG; acne inversa; adalimumab; biomarkers; carbon dioxide laser; clindamycin; comorbidities; ertapenem; finasteride; guidelines; hidradenitis suppurativa; infliximab; laser; lifestyle modification; microbiome; oral contraceptive pills; rifampin; spironolactone
Mesh:
Substances:
Year: 2019 PMID: 30872149 PMCID: PMC9131892 DOI: 10.1016/j.jaad.2019.02.068
Source DB: PubMed Journal: J Am Acad Dermatol ISSN: 0190-9622 Impact factor: 15.487